Article Text

Download PDFPDF
Stage I Noninvasive and Minimally Invasive Uterine Serous Carcinoma: Comprehensive Staging Associated With Improved Survival
  1. Robert L. Giuntoli, MD*,
  2. Melissa A. Gerardi, PA*,
  3. Anna V. Yemelyanova, MD,
  4. Stefanie M. Ueda, MD,
  5. Aimee C. Fleury, MD*,
  6. Teresa P. Diaz-Montes, MD* and
  7. Robert E. Bristow, MD§
  1. *The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, and
  2. Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD;
  3. Department of Obstetrics, Gynecology, and Reproductive Sciences, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA; and
  4. §Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine Medical Center, Orange, CA.
  1. Address correspondence and reprint requests to Robert L. Giuntoli, II, MD, The Kelly Gynecologic Oncology Service, The Johns Hopkins Medical Institutions, 600 N Wolfe St, Phipps #281, Baltimore, MD 21287. E-mail: rgiunto1@jhmi.edu.

Abstract

Objective The aim of this study was to determine if comprehensive surgical staging is a better predictor of outcome than incomplete staging for women with stage I noninvasive or minimally invasive (⩽3 mm) uterine serous carcinoma (USC).

Methods Retrospective chart review was used to identify patients undergoing hysterectomy at the Johns Hopkins Hospital from 1989 to 2010. Relevant clinical and pathologic data were extracted. Patients with noninvasive and minimally invasive (⩽3-mm myometrial invasion) USC were identified. Stage was assigned based on the 2009 International Federation of Gynecology and Obstetrics endometrial cancer criteria. Survival curves were generated using the Kaplan-Meier method.

Results We identified 63 patients with noninvasive or minimally invasive (⩽3 mm) USC. Stages I, II, III, and IV disease were noted in 65% (41/63), 6% (4/63), 14% (9/63), and 14% (9/63) of the patients, respectively. Lower stage was associated with a significantly improved disease-specific survival (P = 0.001). Comprehensive staging, including total hysterectomy, bilateral salpingo-oophorectomy, pelvic and para-aortic lymphadenectomy, omentectomy, and peritoneal biopsies, was completed in 29% (12/41) of the patients with stage I disease. There were no disease-specific deaths in the comprehensive staging group. Compared with incomplete staging, comprehensive staging was associated with a significantly improved disease-specific survival (P = 0.039).

Conclusions Patients with stage I noninvasive and minimally invasive USC on comprehensive staging have an excellent prognosis. Adjuvant therapy may not benefit this patient population.

  • Uterine serous carcinoma
  • Surgical staging
  • Adjuvant therapy

Statistics from Altmetric.com

Footnotes

  • The authors declare that they have no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.